Clinical trial
A Randomized Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Combinations With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer Preceded By A Phase 1 Portion
NCT00460603 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Combinations With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer Preceded By A Phase 1 Portion
- Lead sponsor
- Pfizer
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- January 31, 2006
- Completion date
- November 30, 2012
- Enrollment
- 187 (actual)
- Sites
- 106
Conditions
As the registry lists them; a condition with its own page is linked.